Search: WFRF:(Osterhaus A D M E) >
Novel G3/DT adjuvan...
Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine
-
de Sandt, Carolien E. van (author)
-
Kreijtz, Joost H. C. M. (author)
-
Geelhoed-Mieras, Martina M. (author)
-
show more...
-
Vogelzang-van Trierum, Stella E. (author)
-
Nieuwkoop, Nella J. (author)
-
van de Vijver, David A. M. C. (author)
-
Fouchier, Ron A. M. (author)
-
Osterhaus, Albert D. M. E. (author)
-
- Morein, Bror (author)
- Uppsala universitet,Infektionssjukdomar
-
Rimmelzwaan, Guus F. (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2014
- 2014
- English.
-
In: Vaccine. - : Elsevier BV. - 0264-410X .- 1873-2518. ; 32:43, s. 5614-5623
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Vaccines used against seasonal influenza are poorly effective against influenza A viruses of novel subtypes that may have pandemic potential. Furthermore, pre(pandemic) influenza vaccines are poorly immunogenic, which can be overcome by the use of adjuvants. A limited number of adjuvants has been approved for use in humans, however there is a need for alternative safe and effective adjuvants that can enhance the immunogenicity of influenza vaccines and that promote the induction of broad-protective T cell responses. Here we evaluated a novel nanoparticle, G3, as an adjuvant for a seasonal trivalent inactivated influenza vaccine in a mouse model. The G3 adjuvant was formulated with or without steviol glycosides (DT, for diterpenoid). The use of both formulations enhanced the virus-specific antibody response to all three vaccine strains considerably. The adjuvants were well tolerated without any signs of discomfort. To assess the protective potential of the vaccine-induced immune responses, an antigenically distinct influenza virus strain, A/Puerto Rico/8/34 (A/PR/8/34), was used for challenge infection. The vaccine-induced antibodies did not cross-react with strain A/PR/8/34 in HI and VN assays. However, mice immunized with the G3/DT-adjuvanted vaccine were partially protected against A/PR/8/34 infection, which correlated with the induction of anamnestic virus-specific CD8(+) T cell responses that were not observed with the use of G3 without DT. Both formulations induced maturation of human dendritic cells and promoted antigen presentation to a similar extent. In conclusion, G3/DT is a promising adjuvant formulation that not only potentiates the antibody response induced by influenza vaccines, but also induces T cell immunity which could afford broader protection against antigenically distinct influenza viruses.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Keyword
- Adjuvant
- Split virion vaccine
- T cells
- Heterosubtypic immunity
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Vaccine
(Search for host publication in LIBRIS)
To the university's database